Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.
Chlamydia trachomatis is the leading cause of bacterial sexually transmitted disease worldwide, and despite significant advances in chlamydial research, a prophylactic vaccine has yet to be developed. This Gram-negative obligate intracellular bacterium, which often causes asymptomatic infection, may cause pelvic inflammatory disease (PID), ectopic pregnancies, scarring of the fallopian tubes, miscarriage, and infertility when left untreated. In the genital tract, Chlamydia trachomatis infects primarily epithelial cells and requires Th1 immunity for optimal clearance. This review first focuses on the immune cells important in a chlamydial infection. Second, we summarize the research and challenges associated with developing a chlamydial vaccine that elicits a protective Th1-mediated immune response without inducing adverse immunopathologies.
Materno-Fetal & Obstetrics Research Unit, Department of Obstetrics and Gynecology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Sam
S
Vasilevsky
Gilbert
G
Greub
Denise
D
Nardelli-Haefliger
David
D
Baud
D056704:Adaptive Immunity; D001428:Bacterial Vaccines / Q000276:immunology* / Q000302:isolation & purification; D002692:Chlamydia trachomatis / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007113:Immunity, Innate; D008219:Lymphogranuloma Venereum / Q000276:immunology* / Q000517:prevention & control*
D001428:Bacterial Vaccines